Axsome Therapeutics Inc (MEX:AZSM)
MXN 1519 0 (0%) Market Cap: 87.99 Bil Enterprise Value: 85.49 Bil PE Ratio: 0 PB Ratio: 42.28 GF Score: 36/100

Axsome Therapeutics Inc AXS-12 CONCERT Results Call Transcript

Dec 03, 2019 / 01:00PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics Conference Call. (Operator Instruction] As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.

Mark L. Jacobson
Axsome Therapeutics, Inc. - COO & Secretary

Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the CONCERT Phase II trial of AXS-12 in patients with narcolepsy. A press release announcing that AXS-12 achieved a primary endpoint in the trial crossed the wire a short time ago, and is available on our website at axsome.com.

During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and the intended utilization of investigational agents, our clinical and nonclinical plans, our plans to present or report

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot